Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Cited In for PubMed (Select 20937814)

1.

Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.

Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin MC, Roubtsova A, Hamelin J, Marcinkiewicz J, Chamberland A, Guillemot J, Mayer G, Sisodia SS, Jacob Y, Prat A, Seidah NG.

J Biol Chem. 2015 Jul 24;290(30):18609-20. doi: 10.1074/jbc.M115.647180. Epub 2015 Jun 17.

PMID:
26085104
2.

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9.

Budha NR, Leabman M, Jin JY, Wada DR, Baruch A, Peng K, Tingley WG, Davis JD.

AAPS J. 2015 Jul;17(4):881-90. doi: 10.1208/s12248-015-9750-8. Epub 2015 Mar 31.

PMID:
25823668
3.

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).

Schulz R, Schlüter KD, Laufs U.

Basic Res Cardiol. 2015 Mar;110(2):4. doi: 10.1007/s00395-015-0463-z. Epub 2015 Jan 20.

4.

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.

Lagace TA.

Curr Opin Lipidol. 2014 Oct;25(5):387-93. doi: 10.1097/MOL.0000000000000114. Review.

5.

Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.

Ly K, Saavedra YG, Canuel M, Routhier S, Desjardins R, Hamelin J, Mayne J, Lazure C, Seidah NG, Day R.

J Biol Chem. 2014 Jun 20;289(25):17732-46. doi: 10.1074/jbc.M113.541094. Epub 2014 May 7.

6.

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

Poirier S, Mayer G.

Drug Des Devel Ther. 2013 Oct 4;7:1135-48. doi: 10.2147/DDDT.S36984. eCollection 2013. Review.

7.

PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.

Saavedra YG, Zhang J, Seidah NG.

PLoS One. 2013 Aug 12;8(8):e72113. doi: 10.1371/journal.pone.0072113. eCollection 2013.

8.

The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions.

Seidah NG, Sadr MS, Chrétien M, Mbikay M.

J Biol Chem. 2013 Jul 26;288(30):21473-81. doi: 10.1074/jbc.R113.481549. Epub 2013 Jun 17. Review.

9.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.

PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145. Print 2013.

10.

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.

Mayne J, Ooi TC, Raymond A, Cousins M, Bernier L, Dewpura T, Sirois F, Mbikay M, Davignon J, Chrétien M.

Lipids Health Dis. 2013 May 10;12:70. doi: 10.1186/1476-511X-12-70.

11.

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.

Kosenko T, Golder M, Leblond G, Weng W, Lagace TA.

J Biol Chem. 2013 Mar 22;288(12):8279-88. doi: 10.1074/jbc.M112.421370. Epub 2013 Feb 11.

12.

Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.

Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, Prat A.

Neoplasia. 2012 Dec;14(12):1122-31.

13.

The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.

Saavedra YG, Day R, Seidah NG.

J Biol Chem. 2012 Dec 21;287(52):43492-501. doi: 10.1074/jbc.M112.394023. Epub 2012 Oct 26.

14.

Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation.

Benjannet S, Hamelin J, Chrétien M, Seidah NG.

J Biol Chem. 2012 Sep 28;287(40):33745-55. Epub 2012 Aug 8.

15.

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.

Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, Prat A, Wassef H, Davignon J, Hajjar KA, Mayer G.

PLoS One. 2012;7(7):e41865. doi: 10.1371/journal.pone.0041865. Epub 2012 Jul 27.

16.

The PCSK9 decade.

Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK.

J Lipid Res. 2012 Dec;53(12):2515-24. doi: 10.1194/jlr.R026658. Epub 2012 Jul 17. Review.

17.

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.

Holla ØL, Cameron J, Tveten K, Strøm TB, Berge KE, Laerdahl JK, Leren TP.

J Lipid Res. 2011 Oct;52(10):1787-94. doi: 10.1194/jlr.M018093. Epub 2011 Jul 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk